fingolimod teva 0,5 mg tvrde kapsule
teva gmbh, graf-arco-str. 3, ulm, njemačka - fingolimodklorid - kapsula, tvrda - 0,5 mg - urbroj: svaka kapsula sadrži 0,5 mg fingolimoda (u obliku fingolimodklorida)
tandemact
cheplapharm arzneimittel gmbh - pioglitazone, glimepirida - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - glubravu je indiciran za liječenje bolesnika s tip 2 dijabetes mellitus koji pokazuju nepodnošenja metformina ili kojih metformin je kontraindiciran i koji se već liječe kombinacijom pioglitazon i glimepiridom.
aldactone 25 mg obložene tablete
esteve pharmaceuticals gmbh, hohenzollerndamm 150-151, berlin, njemačka - spironolakton - obložena tableta - 25 mg - urbroj: 1 tableta sadrži 25 mg spironolaktona
pentasa 1 g čepići
ferring gmbh, wittland 11, kiel, njemačka - mesalazin - čepić - 1 g - urbroj: 1 čepić sadrži 1 g mesalazina
pentasa 500 mg tablete s produljenim oslobađanjem
ferring gmbh, wittland 11, kiel, njemačka - mesalazin - tableta s produljenim oslobađanjem - 500 mg - urbroj: 1 tableta s produljenim oslobađanjem sadrži 500 mg mesalazina
kybernin p 500 prašak za otopinu za injekciju ili infuziju
csl behring gmbh, emil-von-behring-str. 76, marburg, njemačka - antitrombin izoliran iz ljudske plazme - prašak i otapalo za otopinu za injekciju/infuziju - 500 iu/bočici (50 iu/ml) - urbroj: jedna bočica s praškom sadrži nominalno 500 iu antitrombina izoliranog iz ljudske plazme nakon rekonstitucije s 10 ml vode za injekcije sadrži približno 50 iu/ml (500 iu/10ml) antitrombina izoliranog iz ljudske plazme
imatinib koanaa
koanaa healthcare gmbh - иматиниба мезилат - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastična sredstva - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. pacijenti koji imaju niske ili vrlo nizak rizik od recidiva, ne bi trebali primati adjuvantne terapije. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. osim po prvi put prijavljene kronične fazi kml, nema kontroliranih istraživanja pokazuju klinički učinak ili povećava stopu preživljavanja kod te bolesti.
pentasa 1 g tablete s produljenim oslobađanjem
ferring gmbh, wittland 11, kiel, njemačka - mesalazin - tableta s produljenim oslobađanjem - urbroj: 1 tableta sadrži 1 g mesalazina
pentasa 2 g granule s produljenim oslobađanjem u vrećici
ferring gmbh, wittland 11, kiel, njemačka - mesalazin - granule s produljenim oslobađanjem u vrećici - urbroj: jedna vrećica sadrži 2 g mesalazina
bortezomib ever pharma 2,5 mg/ml otopina za injekciju
ever valinject gmbh, oberburgau 3, unterach am attersee, austrija - бортезомиб - otopina za injekciju - urbroj: 1 ml otopine za injekciju sadrži 2,5 mg bortezomiba (u obliku estera boronatne kiseline i manitola) jedna bočica s 1 ml otopine za injekciju sadrži 2,5 mg bortezomiba (u obliku estera boronatne kiseline i manitola) jedna bočica s 1,4 ml otopine za injekciju sadrži 3,5 mg bortezomiba (u obliku estera boronatne kiseline i manitola)